^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners

    TEST:
    ArcherMET

    Company:
    Invitae Corp
    Type:
    Other Approval
    Related tests:
    ArcherMET first and only CDx to be approved for the detection of MET gene alterations and it allows for testing of blood and tissue samples from NSCLC patients
    Cancer:
    Non Small Cell Lung Cancer
    Gene:
    MET (MET proto-oncogene, receptor tyrosine kinase)
    Drug:
    Tepmetko (tepotinib)
    Method:
    Circulating tumor DNA (ctDNA)
    Confirmatory trial(s)
    VISION
    ,
    NCT02864992
    |
    N Engl J Med